期刊文献+

Fas/FasL的表达与星型细胞瘤分化关系的探讨

Study on the relationship between the expression of Fas/FasL gene and the differentiation of astrocytoma.
下载PDF
导出
摘要 目的探讨Fas/FasL在人脑星形细胞瘤中的作用与意义.方法应用免疫组化法(S-P法)检测Fas和FasL在不同病理分级的人脑星形细胞瘤中的表达.结果 Fas和FasL在41例星形细胞瘤中阳性细胞的表达率分别为68.3%(28/41)和75.6%(31/41).Fas和FasL的表达水平在Ⅰ~Ⅱ级星形细胞瘤中表达为-或+的分别占95.0%和75.0%,而Ⅲ~Ⅳ级星型细胞瘤中表达为++和+++的分别占71.4%和66.7%.切片观察发现Fas和FasL表达阳性区集中多在缺血坏死灶周围,分别占67.8%和67.7%.Fas/FasL比值随着肿瘤的分级增高而更接近于1.0.结论正常脑组织不表达Fas和FasL,在星形细胞瘤中可见Fas和FasL的表达.在星形细胞瘤中Fax/FasL的表达情况可反映神经胶质细胞间变程度及星形细胞瘤恶性变时瘤细胞增殖的程度. Objective To study the relationship between Fas expression and the differentiation of astrocytoma. Methods The expression intensity of the Fas and FasL in different pathology grade of astrocytoma has been determined by using immunohistochemistry (S-P method).There were totally 50 examples, including 41 astrocytoma examples. Results The expressing rate of positive cell is 68.3%(28/41)and 75.6%(31/41)respectively in 41 case astrocytoma. the expression of Fas/FasL in astrocytoma was certainly associated with their pathology grade. In 41 case, the expression of Fas/fasL which is - or + in 1~2 grades astrocytoma occounted for 95.0% and 75.0% respectively, and occounted for 71.4% and 66.7% respectively in 3~4 grades of astrocytoma. The positive area of Fas/FasL expression concentrated around ischemia and necrosis area after the pathology section in 41 example patients, and occounted for 92.9% and 96.8% respectively. Conclusion Normal brain tissue does not express Fas/FasL, but the expressing of Fas/FasL can be found in astrocytoma. The expressing of Fas/FasL can reflect the anaplastic level of glioma and the tumour cell doubling extent when astrocytoma becomes malignant.
出处 《中国热带医学》 CAS 2005年第5期968-971,931,共5页 China Tropical Medicine
关键词 星形细胞瘤 FAS/FASL 免疫组化法(S-P法) 细胞凋亡 Astrocytoma Fas FasL Apoptosis Immunohistochemistry (S-P method)
  • 相关文献

参考文献18

  • 1Parkin DM, Muir CS, Whelan SL,etal. Cancer incidence in five continents [A]. Vol Ⅵ.IARC Scientific Publication No 120.World Health Organization, International Agency for Research on Cancer, Lyon. France 1992.
  • 2Nagata S, Golstein P. The Fas death factor[J]. Science, 1995;267(5203):1449-1456.
  • 3Weller M, Malipiero U,Rensing Ehl A. Fas/APO - 1 gene trans - fer for human malignant glioma[J]. Cancer Res, 1995; 55(13): 2936-2944.
  • 4Schmitt CA, Lowe SW. Apoptosis and therapy[J]. J. Pathol, 1999, 187(1): 127-137.
  • 5Trauth BC, Klas C, Peters AMJ et al. Monoclonal antbody mediated tumor r egression by induction of apoptosis[J]. Science, 1989: 245~301.
  • 6Yonehara S, Ishii A,Yonehara M.A cell - killing monocional antibody (anti-Fas)to a cell surface antigen co - down regulated with the receptor of tumor necros is factor[J]. J Exp Med, 1989,169.
  • 7Owen Schaub LB,Radinsky R,Kruzei E et al. Anti Fas on nonhematopoietic tumors: Levels of Fas/APO - 1 and Bcl - 2 are not predicitive of biological responsivenes[ J]. Cancer Res, 1994,54:1580~1587.
  • 8Gratas C, Tohma Y, van Meir EG, et al. Fas ligand expression in glioblasroma cell lines and primary astrocytic brain tumors [J]. Brain Pathology,2000,7(3) :863~869.
  • 9Frankel B , Longo SL, Ryken TC. Co - expression of Fas and Fas ligand in human non - astrocytie glial tumors [J].Acta Neuropathol, 1999, 98 (4):363~366.
  • 10Frankcl B, Longo SL, Ryken TC. Human astrocytomas co- expressing Fas and Fas ligand also produce TGFbeta2 and Bcl - 2 [J].J Neurooncol,1999,44(3):205~212.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部